Comparative analysis of GMO regulatory requirements for AAV vectors in the EU and Japan focusing on the shedding data and containment measures [0.03%]
欧盟和日本AAV载体转基因监管要求的比较分析聚焦脱落数据及管控措施
Hirokuni Mizoguchi,Tobias Fleischmann,Masato Komuro et al.
Hirokuni Mizoguchi et al.
Introduction: Recombinant viral-based gene therapy products, such as those incorporating adeno-associated viruses (AAVs), fall under the category of genetically modified organisms (GMOs). The European Union (EU) countries...
Review of emerging biological therapies for recurrent and advanced metastatic cervical cancer [0.03%]
复发性及晚期转移性宫颈癌的新型生物治疗药物进展评述
Virginia E Fontenot,Alex Francoeur,Krishnansu Tewari
Virginia E Fontenot
Checkpoint inhibition for early-stage hormone receptor-positive breast cancer [0.03%]
激素受体阳性早期乳腺癌的检查点抑制剂疗法
Ilana Schlam,Chiara Corti,Sarah Sammons et al.
Ilana Schlam et al.
Introduction: Most patients with breast cancer have early-stage hormone receptor (HR)-positive, human epidermal growth factor receptor-2 (HER2)-negative disease. Even though the prognosis for most of these patients is goo...
Predisposition to conjunctivitis and male sex reduces drug survival of dupilumab in adults and adolescents [0.03%]
预先存在的结膜炎和男性性别降低了Dupixent成人和青少年患者的用药依从性
Luca Mastorino,Irene Richiardi,Federica Gelato et al.
Luca Mastorino et al.
Background: There are currently limited data on dupilumab drug survival (DS), especially on factors possibly associated with drug discontinuation. Materia...
Treatment options for advanced hepatocellular carcinoma: the potential of biologics [0.03%]
晚期肝细胞癌的治疗选择：生物制剂的潜力
Federico Rossari,Silvia Foti,Silvia Camera et al.
Federico Rossari et al.
Introduction: Advanced hepatocellular carcinoma (HCC) represents a significant global health burden, whose treatment has been recently revolutionized by the advent of biologic treatments. Despite that, innovative therapeu...
Targeting gut and intratumoral microbiota: a novel strategy to improve therapy resistance in cancer with a focus on urologic tumors [0.03%]
靶向肠道和瘤内微生物群：一种针对癌症（以泌尿系统肿瘤为重点）治疗抵抗性的新策略
Bingquan Wu,Chao Quan,Yunbo He et al.
Bingquan Wu et al.
Introduction: Growing attention has been drawn to urologic tumors due to their rising incidence and suboptimal clinical treatment outcomes. Cancer therapy resistance poses a significant challenge in clinical oncology, lim...
Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 administered by auto-injector or pre-filled syringe: a randomized, open‑label, single-dose phase I study [0.03%]
托珠单抗类似物CT-P47自动注射器或预装注射器给药的药代动力学和安全性：一项随机、开放标签、单次给药I期临床试验
Kyung-Sang Yu,Hyunwook Ryu,Dongseong Shin et al.
Kyung-Sang Yu et al.
Background: This study compared the pharmacokinetics (PK), immunogenicity, and safety of candidate tocilizumab biosimilar, CT-P47, administered via auto-injector (CT-P47 AI) or pre-filled syringe (CT-P47 PFS), in healthy ...
How close are we to a success stratification tool for improving biological therapy in ulcerative colitis? [0.03%]
我们距离成功地开发出一种工具以改善溃疡性结肠炎的生物疗法还有多远？
Panu Wetwittayakhlang,Gynter Kotrri,Talat Bessissow et al.
Panu Wetwittayakhlang et al.
Introduction: Biological therapies have become the standard treatment for ulcerative colitis (UC). However, clinical remission rates post-induction therapy remain modest at 40-50%, with many initial responders losing resp...
Shama Shishodia,Nora Haloob,Claire Hopkins
Shama Shishodia
Introduction: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a prevalent inflammatory condition with heterogenous underlying endotypes, the most common being type 2 mediated inflammation. Several biologics have been...
Do we need alternative PD-1 inhibitors for the treatment of renal cell carcinoma? [0.03%]
我们还需要用于治疗肾细胞癌的替代PD-1抑制剂吗？
Matteo Rosellini,Andrea Marchetti,Elisa Tassinari et al.
Matteo Rosellini et al.